AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02140450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine
Description: Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
Study NCT02140450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
Study NCT02140450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
Study NCT02612480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid lysinate
Description: 7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
Study NCT02612480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid lysinate
Description: 7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
Study NCT02612480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid lysinate
Description: 7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
Study NCT02612480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 day treatment with placebo
Study NCT02789384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery
Description: Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices.
Study NCT02560662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call.
Study NCT05058209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide extended-release injectable suspension
Description: Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
Study NCT05058209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Description: Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
Study NCT02309112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A mind-body therapy that includes specified breathing, meditation and physical postures.
Study NCT04501861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Vasopressin (20 IU/100 ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
Study NCT04501861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine (4 mg/250ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
Study NCT03767725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.
Study NCT02530814 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Description: Onetime blood collection.
Study NCT00314067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care
Study NCT00314067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care
Study NCT00314067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physician training
Study NCT00314067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Practice team training
Study NCT02723058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICMHM
Description: ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
Study NCT04449848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting after intra tympanic injection
Description: Sitting after intra tympanic injection
Study NCT03837808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
Study NCT03837808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
Study NCT03522805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity non-invasive ventilation
Description: Single night of high-intensity non-invasive ventilation
Study NCT04008797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.
Study NCT04008797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.
Study NCT04008797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin dosing.
Study NCT04008797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel dosing.
Study NCT02121678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~* Week 0-4: 70-80 % of 1-RM~* Week 5-8: 75-86 % of 1-RM~* Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~* MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~* CIDP patients train knee (flexion/extension) and elbow (flexion/extension)
Study NCT02121678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data.
Study NCT01770301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT01770301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01770301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02478346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium
Description: Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
Study NCT00187915 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil + Tacrolimus
Description: Target MPA exposure to 30-60 mg/L/h during first month post-transplant
Study NCT00187915 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil + Cyclosporin
Description: Target MPA exposure to 30-60 mg/L/h during first month post-transplant
Study NCT04262765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril, Amlodipine and Atorvastatin
Description: compare the pharmacokinetic of ramipril (and ramiprilat), atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
Study NCT04763811 — intervention group
Intervention type: OTHER
Intervention: Focus groups
Description: discussion between participants about representations of health, dependance, fragility, and new technologies
Study NCT04763811 — intervention group
Intervention type: OTHER
Intervention: Individual interviews
Description: Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
Study NCT03139396 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tub shaped inlay bridge design
Description: inlay retained bridge with tub shaped retainer on both abutments
Study NCT03139396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tub shaped inlay bridge design
Description: inlay retained bridge with tub shaped retainer on both abutments
Study NCT01536041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 200 mg QD, single dose
Study NCT01536041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 20 mg QD, single dose
Study NCT01536041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10 mg Montelukast, QD single dose
Study NCT01536041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
Study NCT03853460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: ultrasound low frequency probe will be used to determine the depth of the posterior complex to assists placement of midline thoracic epidural
Study NCT01119534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaiacol, eucalyptol, menthol and camphor suppository
Description: 2 times per day
Study NCT03853460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block catheter
Description: ultrasound guided placement of bilateral quadratus lumborum catheters
Study NCT03410615 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
Study NCT03410615 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
Study NCT03410615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m2 days 1, 22, 43 concurrently with RT
Study NCT03410615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given in concurrent and adjuvant phase
Study NCT03410615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: ARM CLOSED TO ACCRUAL - 2019
Study NCT01119534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guaiacol suppository
Description: 2 times per day
Study NCT01119534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guaifenesin syrup
Description: 4.19 mL - 4 in 4 hours
Study NCT04148911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
Study NCT04148911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
Study NCT03302871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Study NCT03302871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study NCT03302871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT01438463 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
Study NCT01438463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites 6,667 AU/ml
Description: Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
Study NCT01438463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites 20,000 AU/ml
Description: Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
Study NCT01438463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites 50,000 AU/ml
Description: Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
Study NCT01438463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites 100,000 AU/ml
Description: Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
Study NCT04598906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual environment rehabilitation
Description: The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.
Study NCT04598906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paper-pencil rehabilitation
Description: The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
Study NCT03302871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid training model of CIMT and BIT
Study NCT03302871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study NCT03777553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for Justice-Involved Veterans
Description: Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
Study NCT03216252 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: samples
Description: Blood samples, oral smear and urine
Study NCT02515526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
Description: Reference period
Study NCT02515526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
Description: Test period
Study NCT03256760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin
Study NCT03256760 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03325608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POISED Care
Description: Program of dementia care management.
Study NCT03170453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
Study NCT03049306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol Oral Tablet
Description: Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
Study NCT03170453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Supportive Therapy
Description: An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
Study NCT03836911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serious game
Description: Effect of serious game on elderly in comparison of the physical activity adapted meeting
Study NCT03836911 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: classic program
Description: Effect of serious game on elderly in comparison of the physical activity adapted meeting
Study NCT04289480 — intervention group
Intervention type: DEVICE
Intervention: ENTERPRISE 2 device
Description: The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
Study NCT03049306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Oral Tablet
Description: Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
Study NCT03049306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
Study NCT03049306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)